# Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)

> **NCT01163149** · PHASE2 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 19 (actual)

## Conditions studied

- Hypophosphatasia

## Interventions

- **DRUG:** asfotase alfa
- **DRUG:** asfotase alfa

## Key facts

- **NCT ID:** NCT01163149
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2019-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01163149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01163149, "Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01163149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*